Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

GU Cancers 2021 | ASCO GU 2021 highlights: enfortumab vedotin, oral docetaxel and 177Lu-PSMA-617

Name: ASCO GU 2021 highlights: enfortumab vedotin, oral docetaxel and 177Lu-PSMA-617
Uploaded: 2021-02-16T00:00:00Z
Duration: 50 s
Description: Alison Birtle, MRCP, FRCR, MD, Lancashire Teaching Hospitals, Preston, UK, shares her highlights from ASCO GU 2021, in particular discussing the promising results seen with studies of the antibody-drug conjugate enfortumab vedotin, oral docetaxel and 177Lu-PSMA-617 versus cabazitaxel. This interview took place during the 2021 Genitourinary Cancers Symposium.

Alison Birtle • 16 Feb 2021

GU Cancers 2021

Genitourinary Cancer Prostate Cancer 177Lu-PSMA-617 Antibodies Cabazitaxel Docetaxel Enfortumab vedotin

Alison Birtle, MRCP, FRCR, MD, Lancashire Teaching Hospitals, Preston, UK, shares her highlights from ASCO GU 2021, in particular discussing the promising results seen with studies of the antibody-drug conjugate enfortumab vedotin, oral docetaxel and 177Lu-PSMA-617 versus cabazitaxel. This interview took place during the 2021 Genitourinary Cancers Symposium.

Disclosures

Alison Birtle, MRCP, FRCR, MD, has received research support from Sanofi Aventis, and has participated in advisory boards or provided educational support to Janssen, Astellas, Bayer, Roche, BMS, Pfizer, Sanofi Aventis and MSD.